Cargando…

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma

While there are various attempts to administer COVID-19-convalescent plasmas to SARS-CoV-2-infected patients, neither appropriate approach nor clinical utility has been established. We examined the presence and temporal changes of the neutralizing activity of IgG fractions from 43 COVID-19-convalesc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maeda, Kenji, Higashi-Kuwata, Nobuyo, Kinoshita, Noriko, Kutsuna, Satoshi, Tsuchiya, Kiyoto, Hattori, Shin-ichiro, Matsuda, Kouki, Takamatsu, Yuki, Gatanaga, Hiroyuki, Oka, Shinichi, Sugiyama, Haruhito, Ohmagari, Norio, Mitsuya, Hiroaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946899/ https://www.ncbi.nlm.nih.gov/pubmed/33692457 http://dx.doi.org/10.1038/s41598-021-84733-5

Ejemplares similares

Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants
por: Tsuchiya, Kiyoto, et al.
Publicado: (2023)

Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro
por: Hattori, Shin-ichiro, et al.
Publicado: (2018)

Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma
por: Inada, Makoto, et al.
Publicado: (2023)

Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C–induced HIV latency reversal
por: Matsuda, Kouki, et al.
Publicado: (2019)

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
por: Takamatsu, Yuki, et al.
Publicado: (2022)

Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19
por: Kutsuna, Satoshi, et al.
Publicado: (2021)

Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies
por: Inada, Makoto, et al.
Publicado: (2021)

SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response
por: Takamatsu, Yuki, et al.
Publicado: (2022)

SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response
por: Takamatsu, Yuki, et al.
Publicado: (2022)

Hemoptysis and a Newly Formed Lung Bulla in a Case of Convalescent COVID-19 Pneumonia
por: Sato, Lubna, et al.
Publicado: (2021)

Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19
por: Sugiyama, Masaya, et al.
Publicado: (2021)

A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes
por: Takamatsu, Yuki, et al.
Publicado: (2023)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors
por: Hayashida, Tsunefusa, et al.
Publicado: (2017)

Residual and Late Onset Symptoms Appeared in a Patient with Severe Fever with Thrombocytopenia in a Convalescence Stage
por: Kanda, Kohei, et al.
Publicado: (2021)

Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals
por: Terada, Mari, et al.
Publicado: (2023)

A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT)
por: Tomita, Noriko, et al.
Publicado: (2022)

Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study
por: Yamamoto, Shohei, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan
por: Yamamoto, Shohei, et al.
Publicado: (2021)

Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan
por: Tanaka, Akihito, et al.
Publicado: (2021)

A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators
por: Matsuda, Kouki, et al.
Publicado: (2021)

Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
por: Yamamoto, Shohei, et al.
Publicado: (2023)

GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection
por: Hattori, Shin-ichiro, et al.
Publicado: (2020)

Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved
por: Suzuki, Tetsuya, et al.
Publicado: (2023)

Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism
por: Tsuchiya, Kiyoto, et al.
Publicado: (2013)

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine
por: Yasutake, Yoshiaki, et al.
Publicado: (2020)

No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity
por: Nomoto, Hidetoshi, et al.
Publicado: (2021)

A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies
por: Noda, Kenta, et al.
Publicado: (2021)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
por: Khor, Seik-Soon, et al.
Publicado: (2022)

Generation of Angiotensin-Converting Enzyme 2/Transmembrane Protease Serine 2-Double-Positive Human Induced Pluripotent Stem Cell-Derived Spheroids for Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Drug Evaluation
por: Higashi-Kuwata, Nobuyo, et al.
Publicado: (2022)

Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination
por: Okumura, Nobumasa, et al.
Publicado: (2022)

HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir
por: Yasutake, Yoshiaki, et al.
Publicado: (2018)

Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
por: Inada, Makoto, et al.
Publicado: (2022)

Restoration of Neutralization Activity Against Omicron BA.2 and BA.5 in Older Adults and Individuals With Risk Factors Following the Fourth Dose of Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Vaccine
por: Amano, Masayuki, et al.
Publicado: (2022)

A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro
por: Matsuda, Kouki, et al.
Publicado: (2021)

Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals
por: Maeda, Kenji, et al.
Publicado: (2021)

Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
por: Maeda, Kenji, et al.
Publicado: (2021)

Pharmacokinetics of Bictegravir in Older Japanese People Living with HIV-1
por: Kawashima, Akira, et al.
Publicado: (2023)

Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2–Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan
por: Amano, Masayuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fb8qfsnhk0t3o9t6g368n6o7p8